File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: A systematic review and meta-analysis

TitleTranscatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
Authors
KeywordsChemicals And Cas Registry Numbers
Issue Date2009
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/radonc
Citation
Radiotherapy and Oncology, 2009, v. 92 n. 2, p. 184-194 How to Cite?
AbstractBackground and Purpose: To evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) plus radiotherapy (RT) for unresectable hepatocellular carcinoma (UHCC) using meta-analysis of data from the literature involving available randomized controlled trials of TACE in combination with RT compared with that of TACE alone (Therapy I versus II) in treating UHCC. Material and Methods: We searched the Cochrane Library, MEDLINE, CENTRAL, EMBASE, CBMdisc, and CNKI as well as employing manual searches. Meta-analysis was performed on the results of homogeneous studies. Analyses subdivided by study design were also performed. Results: We found 17 trials involving 1476 patients. 5 of total were Randomized Controlled Trials (RCTs) and 12 were Non-randomized Controlled Clinical Trials (CCTs). In terms of quality, 5 RCTs were graded B, and 12 CCTs were graded C. Our results showed that Therapy I, compared with Therapy II, significantly improved the survival and the tumor response of patients, and was thus more therapeutically beneficial. Serious adverse events were not increased exception for total bilirubin (TB) level. Conclusions: Therapy I was more therapeutically beneficial. However, considering the strength of the evidence, additional randomized controlled trials are needed before Therapy I can be recommended routinely. © 2008 Elsevier Ireland Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/92351
ISSN
2015 Impact Factor: 4.817
2015 SCImago Journal Rankings: 2.654
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMeng, M-Ben_HK
dc.contributor.authorCui, Y-Len_HK
dc.contributor.authorLu, Yen_HK
dc.contributor.authorShe, Ben_HK
dc.contributor.authorChen, Yen_HK
dc.contributor.authorGuan, Y-Sen_HK
dc.contributor.authorZhang, R-Men_HK
dc.date.accessioned2010-09-17T10:43:29Z-
dc.date.available2010-09-17T10:43:29Z-
dc.date.issued2009en_HK
dc.identifier.citationRadiotherapy and Oncology, 2009, v. 92 n. 2, p. 184-194en_HK
dc.identifier.issn0167-8140en_HK
dc.identifier.urihttp://hdl.handle.net/10722/92351-
dc.description.abstractBackground and Purpose: To evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) plus radiotherapy (RT) for unresectable hepatocellular carcinoma (UHCC) using meta-analysis of data from the literature involving available randomized controlled trials of TACE in combination with RT compared with that of TACE alone (Therapy I versus II) in treating UHCC. Material and Methods: We searched the Cochrane Library, MEDLINE, CENTRAL, EMBASE, CBMdisc, and CNKI as well as employing manual searches. Meta-analysis was performed on the results of homogeneous studies. Analyses subdivided by study design were also performed. Results: We found 17 trials involving 1476 patients. 5 of total were Randomized Controlled Trials (RCTs) and 12 were Non-randomized Controlled Clinical Trials (CCTs). In terms of quality, 5 RCTs were graded B, and 12 CCTs were graded C. Our results showed that Therapy I, compared with Therapy II, significantly improved the survival and the tumor response of patients, and was thus more therapeutically beneficial. Serious adverse events were not increased exception for total bilirubin (TB) level. Conclusions: Therapy I was more therapeutically beneficial. However, considering the strength of the evidence, additional randomized controlled trials are needed before Therapy I can be recommended routinely. © 2008 Elsevier Ireland Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/radoncen_HK
dc.relation.ispartofRadiotherapy and Oncologyen_HK
dc.subjectChemicals And Cas Registry Numbersen_HK
dc.titleTranscatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: A systematic review and meta-analysisen_HK
dc.typeArticleen_HK
dc.identifier.emailChen, Y:ychenc@hkucc.hku.hken_HK
dc.identifier.authorityChen, Y=rp1318en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.radonc.2008.11.002en_HK
dc.identifier.pmid19042048-
dc.identifier.scopuseid_2-s2.0-67650896445en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-67650896445&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume92en_HK
dc.identifier.issue2en_HK
dc.identifier.spage184en_HK
dc.identifier.epage194en_HK
dc.identifier.isiWOS:000269088400005-
dc.identifier.citeulike5469737-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats